Quick Answer
RIGEL PHARMACEUTICALS INC reported R&D Expense of $33.30 million for fiscal year 2025.
RIGEL PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $33.30M | +42.4% |
| 2024 | $23.38M | -4.7% |
| 2023 | $24.52M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2011 | $17.11M | +1.7% | +1.7% |
| June 30, 2010 | $16.82M | — | — |
- RIGEL PHARMACEUTICALS INC showed an increase of +42.4% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, RIGEL PHARMACEUTICALS INC’s r&d expense has grown by 35.8% (from $24.52 million to $33.30 million).
- The most recent figure is from RIGEL PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: